Search results for "Lymphocyte"

showing 10 items of 2280 documents

Liver cirrhosis associated with heterozygous alpha-1-antitrypsin deficiency type Pi MS and autoimmune features.

1995

Patients with homozygous protease inhibitor (Pi) type ZZ or a few rare M-like types may develop liver cirrhosis due to intracellular storage of alpha-antitrypsin (AAT), whereas some patients with heterozygous Pi MZ or SZ normally present with transient abnormal liver function tests in childhood. We report a 42-year-old obese patient who developed liver cirrhosis in association with heterozygous Pi MS (AAT) deficiency. Immunohistological and electron microscope examination showed storage of AAT in the hepatocytes. Interestingly, autoimmune features in this patient suggest that abnormal immune responses may contribute to the pathology of chronic liver disease.

AdultLiver CirrhosisMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHeterozygoteCirrhosisT-LymphocytesAlpha (ethology)medicine.disease_causeAutoimmunityAutoimmune DiseasesImmunoenzyme TechniquesInternal medicinealpha 1-Antitrypsin DeficiencyPiMedicineHumansProtease inhibitor (pharmacology)ObesityAutoimmune diseaseAlpha 1-antitrypsin deficiencybusiness.industryGastroenterologymedicine.diseaseTrypsin deficiencyFlow CytometryAlcoholismMicroscopy ElectronEndocrinologyPhenotypeLiveralpha 1-AntitrypsinCytokinesbusinessDigestion
researchProduct

Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis.

2005

: Background: Cyclic GMP (cGMP) concentration is increased in plasma of patients with liver cirrhosis. Three possible mechanisms may contribute: increased cGMP synthesis by soluble (activated by nitric oxide), or particulate (activated by atrial natriuretic peptide (ANP)) guanylate cyclase or increased release from cells. Aim: The aim of this work was to analyze the possible contributors to increased plasma cGMP and to assess whether changes in the parameters of the system vary with the degree of liver disease (Child Pugh score) or by the presence of ascites. Methods: We measured cGMP in plasma and lymphocytes, soluble guanylate cyclase activation by nitric oxide in lymphocytes, nitrates an…

AdultLiver CirrhosisMalemedicine.medical_specialtyGUCY1B3Nitric OxideNitric oxidechemistry.chemical_compoundAtrial natriuretic peptideInternal medicinemedicineHumansLymphocytesCyclic GMPCells CulturedNitritesAgedNitratesHepatologyPenicillamineGUCY1A3AscitesMiddle AgedNPR1PDE5 drug designEndocrinologychemistryGuanylate CyclaseCGMP transportAtrial Natriuretic FactorHomeostasisLiver International
researchProduct

Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.

2011

Up to 4 million persons in the USA have chronic hepatitis C (CHC) (1). Despite a decline in overall HCV infections, the number of patients with end stage liver disease due to CHC will increase for the next 2 decades (2). Even with highly effective novel therapies, currently 30–50% of infected individuals fail treatment (3). Therefore, a better understanding of mechanisms involved in CHC-related liver disease progression could permit more efficient therapies. Adaptive effector T cells (frequently assessed by measuring production of prototypic T helper 1 cytokine IFNγ) play an important role in control of HCV infection during the acute phase (4). In CHC, effector HCV-specific T cell immune re…

AdultLiver CirrhosisMalemedicine.medical_treatmentT cellGene ExpressionHepacivirusBiologyCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryCollagen Type IArticleInterferon-gammaImmune systemTransforming Growth Factor betamedicineHepatic Stellate CellsCytotoxic T cellHumansIL-2 receptorAgedHepatologyViral Core ProteinsFOXP3Hepatitis C ChronicMiddle AgedInterleukin-10Collagen Type I alpha 1 ChainInterleukin 10Cytokinemedicine.anatomical_structureCross-Sectional StudiesLiverImmunologyDisease ProgressionFemaleMatrix Metalloproteinase 1CD8Hepatology (Baltimore, Md.)
researchProduct

Correlation of Clinical and Immunologic Parameters of the Inflammatory Activity of Pulmonary Sarcoidosis

1991

The evaluation of activation markers such as T4/T8 ratio and HLA-DR expression of lymphocytes of bronchoalveolar lavage (L-BAL) is an important clinical approach for the staging of sarcoidosis. However, it is not known to what extent this is paralleled by an exaggerated lymphocyte function. We investigated the dependence of L-BAL activation markers on the production of interleukin-2 (IL-2) by L-BAL and on the soluble IL-2 receptor serum level (sIL-2R) in 116 patients with sarcoidosis. In none of the combinations tested was a correlation between the two groups of parameters found; r less than 0.5, upper 90% confidence limit of r less than 0.8. Interestingly, IL-2 production is independent of…

AdultLung DiseasesMalePulmonary and Respiratory MedicineSystemic diseaseSarcoidosisT-LymphocytesLymphocyteCD4-CD8 RatioCD4-CD8 RatioEnzyme-Linked Immunosorbent AssayInflammationLymphocyte ActivationHumansMedicineReceptormedicine.diagnostic_testbusiness.industryRespiratory diseaseReceptors Interleukin-2HLA-DR Antigensrespiratory systemmedicine.diseaserespiratory tract diseasesBronchoalveolar lavagemedicine.anatomical_structureImmunologyInterleukin-2FemaleSarcoidosismedicine.symptombusinessBronchoalveolar Lavage FluidAmerican Review of Respiratory Disease
researchProduct

Spontaneous Monokine Release by Alveolar Macrophages in Chronic Sarcoidosis

1991

In pulmonary sarcoidosis an activation of alveolar T lymphocytes and alveolar macrophages (AM) has been demonstrated. There is evidence that in contrast to acute disease a heightened T-cell response cannot be observed in the chronic phase of sarcoidosis. The role of AM in the inflammatory process of chronic sarcoidosis is not yet intensively evaluated. To address this question we measured the release of tumor necrosis factor alpha (TNFα) and interleukin-1 (IL-1) by AM of 39 patients with chronic sarcoidosis (duration > 4 years; 30 active, 9 inactive diseases) without therapy and correlated the monokine release with parameters of T-cell alveolitis and the course of the disease. The T4/T8 …

AdultLung DiseasesMaleSarcoidosisT-Lymphocytesmedicine.medical_treatmentImmunologyCD4-CD8 Ratio610 MedizinBronchoalveolar Lavage Fluid/immunologyTumor Necrosis Factor-alpha/biosynthesisLymphocyte Activation/immunologyLymphocyte ActivationMacrophages AlveolarmedicineHumansImmunology and AllergyMacrophageAntibodies Monoclonal/immunologyInterleukin-1/biosynthesisddc:610Tumor Necrosis Factor-alphabusiness.industryRespiratory diseaseAntibodies MonoclonalInterleukinGeneral MedicineT-Lymphocytes/immunologymedicine.diseaseSarcoidosis/immunologyMonokineLung Diseases/immunologyCytokinemedicine.anatomical_structureChronic DiseaseImmunologyMacrophages Alveolar/immunologyFemaleTumor necrosis factor alphaSarcoidosisPulmonary alveolusbusinessBronchoalveolar Lavage FluidInterleukin-1International Archives of Allergy and Immunology
researchProduct

Assessment of the cytotoxic potential of an aqueous-ethanolic extract from Thalassia testudinum angiosperm marine grown in the Caribbean Sea

2018

Abstract Objectives Reported antioxidant, anti-inflammatory and neuroprotective properties for one aqueous-ethanolic extract from Thalassia testudinum which grows in the Caribbean Sea compelled us to explore about extract cytotoxic effects. Methods Cell viability was assayed on tumour (HepG2, PC12, Caco-2 and 4T1) and non-tumour (VERO, 3T3, CHO, MCDK and BHK2) cell lines. The extract effects upon primary cultures of rat and human hepatocytes and human lymphocytes were assayed. Key findings The extract exhibited cytotoxicity against cancer cells compared to normal cells, and the IC50 values were 102 μg/ml for HepG2, 135 μg/ml for PC12, 165 μg/ml for Caco-2 and 129 μg/ml for 4T1 cells after 4…

AdultMale0301 basic medicineCell SurvivalDNA damagePrimary Cell CulturePharmaceutical ScienceHydrocharitaceaePC12 CellsRats Sprague-DawleyInhibitory Concentration 5003 medical and health sciencesNeoplasmsAnimalsHumansCytotoxic T cellLymphocytesViability assayCytotoxicityPharmacologyDose-Response Relationship DrugEthanolbiologyPlant ExtractsChemistryPharmacology. TherapyWaterHep G2 Cellsbiology.organism_classificationAntineoplastic Agents PhytogenicMolecular biologyRatsComet assay030104 developmental biologyCaribbean RegionCell cultureThalassia testudinumCancer cellSolventsCaco-2 CellsThalassia testudinum DNA damage cytotoxicity oxidative stressJournal of pharmacy and pharmacology
researchProduct

Proinflammatory CX3CR1+CD59+Tumor Necrosis Factor–Like Molecule 1A+Interleukin‐23+ Monocytes Are Expanded in Patients With Ankylosing Spondylitis and…

2018

Objective: Gut-derived innate lymphoid cell 3 (ILC3) has been shown to participate in the pathogenesis of ankylosing spondylitis (AS). CX3CR1+ mononuclear phagocytes (MNPs) have been demonstrated to modulate ILC3 function in the gut. This study was undertaken to investigate the role of proinflammatory CX3CR1+CD59+ MNPs in modulating ILC3 function in AS patients. Methods: MNP subsets in the blood of AS patients and controls were analyzed by flow cytometry. The presence of CX3CR1+CD59+ cells in tissue was confirmed by confocal microscopy. Expression of the proinflammatory chemokines CX3CL1 and CCL2 and decoy receptor 6 (DcR-6) was analyzed. Peripheral CX3CR1+CD59+ cells were cocultured with I…

AdultMale0301 basic medicineChemokineImmunologyPopulationCX3C Chemokine Receptor 1CD11cCD59 Antigenschemical and pharmacologic phenomenaCCL2Interleukin-23MonocytesProinflammatory cytokineFlow cytometry03 medical and health sciences0302 clinical medicineRheumatologymedicineHumansImmunology and AllergySpondylitis AnkylosingLymphocytesCX3CL1educationMononuclear Phagocyte System030203 arthritis & rheumatologyeducation.field_of_studybiologymedicine.diagnostic_testChemistryInnate lymphoid cellMiddle AgedImmunity Innate030104 developmental biologyReceptors Tumor Necrosis Factor Type ICase-Control Studiesbiology.proteinCancer researchFemaleArthritis & Rheumatology
researchProduct

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis

2017

Abstract The therapeutic mode of action of dimethyl fumarate (DMF), approved for treating patients with relapsing-remitting multiple sclerosis, is not fully understood. Recently, we and others demonstrated that Ab-independent functions of distinct B cell subsets are important in mediating multiple sclerosis (MS) relapsing disease activity. Our objective was to test whether and how DMF influences both the phenotype and functional responses of disease-implicated B cell subsets in patients with MS. High-quality PBMC were obtained from relapsing-remitting MS patients prior to and serially after initiation of DMF treatment. Multiparametric flow cytometry was used to monitor the phenotype and fun…

AdultMale0301 basic medicineDimethyl FumarateImmunologyNaive B cellB-Lymphocyte SubsetsEnzyme-Linked Immunosorbent AssayBiologyPeripheral blood mononuclear cellProinflammatory cytokineFlow cytometryYoung Adult03 medical and health scienceschemistry.chemical_compoundMultiple Sclerosis Relapsing-Remitting0302 clinical medicineIn vivomedicineHumansImmunology and AllergyB cellmedicine.diagnostic_testDimethyl fumarateMultiple sclerosisMiddle AgedFlow Cytometrymedicine.disease030104 developmental biologymedicine.anatomical_structurechemistryImmunologyCancer researchFemaleImmunosuppressive Agents030217 neurology & neurosurgeryThe Journal of Immunology
researchProduct

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells

2016

Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein–kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells.…

AdultMale0301 basic medicineEncephalomyelitis Autoimmune ExperimentalMultiple Sclerosisanimal structuresT-LymphocytesScienceMedizinGeneral Physics and AstronomyKininsCoagulation Factor XIIAdaptive ImmunityBiologymedicine.disease_causeArticleGeneral Biochemistry Genetics and Molecular BiologyReceptors Urokinase Plasminogen ActivatorAutoimmunityYoung Adult03 medical and health sciencesImmune systemddc:570medicineAnimalsHumansddc:610cardiovascular diseasesNeuroinflammationAgedFactor XIIMultidisciplinaryInterleukin-17QExperimental autoimmune encephalomyelitisCell DifferentiationDendritic CellsGeneral ChemistryMiddle Agedmedicine.diseaseAcquired immune systemMice Inbred C57BL030104 developmental biologyNeuroimmunologyFactor XIIImmunologyFemaleKallikreinscirculatory and respiratory physiologyNature Communications
researchProduct

B and T cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing home residents

2021

Objectives The immunogenicity of the Comirnaty® COVID-19 vaccine is understudied in elderly people with comorbidities. SARS-CoV-2-S-targeted antibody and T cell responses following full vaccination were assessed in nursing home residents. Methods Sixty nursing home residents (44 female; age, 53-100 years), of whom 10 had previously been diagnosed of COVID-19, and 18 healthy controls (15 female; age, 27-54 years) were recruited. Pre- and post-vaccination blood specimens were available for quantitation of total antibodies binding SARS-CoV-2 S protein and enumeration of SARS-CoV-2-S-reactive IFN-γ CD4+ and CD8+ T cells by flow cytometry. Results The seroconversion rate in presumably SARS-CoV-2…

AdultMale0301 basic medicineMicrobiology (medical)COVID-19 VaccinesSARS-CoV-2-S antibodiesT-LymphocytesT cell030106 microbiologyNursing home residentsAntibodies ViralFlow cytometryInterferon-gamma03 medical and health sciences0302 clinical medicineImmune systemComirnaty®COVID-19 vaccinemedicineHumans030212 general & internal medicineSeroconversionAgedAged 80 and overB-Lymphocytesbiologymedicine.diagnostic_testbusiness.industrySARS-CoV-2ImmunogenicityImmunityCOVID-19General MedicineMiddle AgedNursing HomesVaccinationInfectious Diseasesmedicine.anatomical_structureSARS-CoV-2-S T cellsSpike Glycoprotein CoronavirusImmunologybiology.proteinFemaleOriginal ArticleAntibodybusinessCD8Clinical Microbiology and Infection
researchProduct